LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/Ascendx Spine Device Granted FDA Clearance
Spine

Ascendx Spine Device Granted FDA Clearance

December 24, 2012 1 min read Premium comments

Advertisement

Ascendx Spine Device Granted FDA Clearance
Courtesy of Ascendx Spine, Inc.
Secondary

The Food and Drug Administration (FDA) has granted 510(k) clearance to the Ascendx VCF Repair System, produced by Ascendx Spine, Inc., of Winter Park, Florida. Previously cleared by the FDA is the company’s Acu-Cut Vertebral Augmentation System. Both products are used to treat vertebral compression fractures (VCF) and both have been approved for marketing in Europe.

A vertebral compression fracture forces a vertebra to collapse. When that happens, the spinal column above the fracture assumes an abnormal forward curve, resulting in back pain and a hunchbacked appearance. Current standard procedures for treating VCFs are vertebroplasty and kyphoplasty. Ascendx officials say that while traditional technologies require passing next to both sides of the spinal cord to reach the entire vertebral body, the Ascendx products are designed to achieve this through minimally invasive single-sided access.

“We are extremely pleased that both of our products, the Ascendx VCF Repair System and the Ascendx Acu-Cut Vertebral Augmentation System, are now FDA-cleared and CE-marked, ” said Julian M. Mackenzie, CEO of Ascendx Spine. “We look forward to commencing the commercialization of both products in the United States and Europe via a hybrid strategy of select spine distributors and a direct sales force.”

Ascendx Spine Inc. is a medical device company focused on the development and commercialization of innovative orthopedic devices for the spine and trauma markets.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy